tradingkey.logo
tradingkey.logo
Search

TELA Bio Inc

TELA
Add to Watchlist
0.706USD
-0.034-4.65%
Close 06/26, 16:00ETQuotes delayed by 15 min
31.59MMarket Cap
LossP/E TTM

More Details of TELA Bio Inc Company

TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.

TELA Bio Inc Info

Ticker SymbolTELA
Company nameTELA Bio Inc
IPO dateNov 08, 2019
CEOKoblish (Antony)
Number of employees209
Security typeOrdinary Share
Fiscal year-endNov 08
Address1 Great Valley Parkway, Suite 24
CityMALVERN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code19355
Phone14843202930
Websitehttps://www.telabio.com/
Ticker SymbolTELA
IPO dateNov 08, 2019
CEOKoblish (Antony)

Company Executives of TELA Bio Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Antony Koblish
Mr. Antony Koblish
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
487.76K
+30.34%
Mr. Jeffrey (Jeff) Blizard
Mr. Jeffrey (Jeff) Blizard
President
President
198.75K
+43.27%
Mr. Paul Talmo
Mr. Paul Talmo
Chief Technology Officer
Chief Technology Officer
110.92K
+44.67%
Dr. Betty Jo Rocchio
Dr. Betty Jo Rocchio
Independent Director
Independent Director
23.60K
+49.47%
Ms. Federica F. O'Brien
Ms. Federica F. O'Brien
Independent Director
Independent Director
14.22K
+55.91%
Mr. Kurt Azarbarzin
Mr. Kurt Azarbarzin
Independent Director
Independent Director
14.22K
+55.91%
Mr. Douglas G. (Doug) Evans
Mr. Douglas G. (Doug) Evans
Independent Chairman of the Board
Independent Chairman of the Board
14.22K
+55.91%
Mr. Vince J. Burgess
Mr. Vince J. Burgess
Independent Director
Independent Director
--
--
Mr. Roberto E. Cuca, J.D.
Mr. Roberto E. Cuca, J.D.
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
--
--
Mr. Greg Firestone
Mr. Greg Firestone
Chief Commercial Officer
Chief Commercial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Antony Koblish
Mr. Antony Koblish
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
487.76K
+30.34%
Mr. Jeffrey (Jeff) Blizard
Mr. Jeffrey (Jeff) Blizard
President
President
198.75K
+43.27%
Mr. Paul Talmo
Mr. Paul Talmo
Chief Technology Officer
Chief Technology Officer
110.92K
+44.67%
Dr. Betty Jo Rocchio
Dr. Betty Jo Rocchio
Independent Director
Independent Director
23.60K
+49.47%
Ms. Federica F. O'Brien
Ms. Federica F. O'Brien
Independent Director
Independent Director
14.22K
+55.91%
Mr. Kurt Azarbarzin
Mr. Kurt Azarbarzin
Independent Director
Independent Director
14.22K
+55.91%

FAQs

Who are the top five shareholders of TELA Bio Inc?

The top five shareholders of TELA Bio Inc are: Mr. Antony Koblish

How many institutions hold shares of TELA Bio Inc (TELA)?

As of 2026Q1, 163 institutions hold shares of TELA Bio Inc, with a combined market value of approximately 32.85M, accounting for 73.39% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -6147477.00.

What is the biggest source of revenue for TELA Bio Inc?

In 2026Q1, the OviTex business generated the highest revenue for TELA Bio Inc, amounting to 51.22M and accounting for 63.81% of total revenue.
KeyAI